Product testing provider Eurofins Scientific (Euronext Paris:ERF) confirmed on Monday that it has completed its acquisition of Infinity Laboratories Inc, expanding its biopharma product testing presence in the United States.
Infinity operates eight labs nationwide, offering microbiology, chemistry, sterilisation and packaging testing services to pharma, biotech and medical device companies.
This acquisition broadens Eurofins' microbiology footprint and complements its existing packaging testing services. It strengthens the company's national and global biopharma testing network, providing clients with a wider range of services and expertise.
Infinity benefits from Eurofins' extensive lab network, analytical capabilities and IT systems.
Abbott launches new clinical trial to improve results in patients with advanced heart failure
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Adocia patents stable hormone combinations for obesity and diabetes
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
Viatris reports positive results for EFFEXOR in GAD treatment in Japan
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices
Conformal Medical reports start of GLACE study
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study